alexa Differentiation Potential of Adipose-Derived Mesenchymal Stem Cells to Osteoblast Cell in Early, Middle and Late Passages

ISSN: 2157-7633

Journal of Stem Cell Research & Therapy

  • Research Article   
  • J Stem Cell Res Ther 2018, Vol 8(5): 426
  • DOI: 10.4172/2157-7633.1000426

Differentiation Potential of Adipose-Derived Mesenchymal Stem Cells to Osteoblast Cell in Early, Middle and Late Passages

Rilianawati R1*, Jennifer Bratakencana1 and Ago Harlim2
1Center of Pharmaceutical and Medical Technology, Agency for the Assessment and Application of Technology, Jakarta, Indonesia
2Dermatovenereology department, Christian Universitas of Indonesia, Jakarta, Indonesia
*Corresponding Author: Rilianawati R, Center of Pharmaceutical and Medical Technology, Agency for the Assessment and Application of Technology, Jakarta, Indonesia, Tel: 62-895353263161, Fax: 62-21-7560707, Email: [email protected], [email protected]

Received Date: May 07, 2018 / Accepted Date: May 18, 2018 / Published Date: May 31, 2018

Abstract

Stem cell-based regenerative therapies are an exciting and emerging field in medicine and dentistry. Since the 1960s, stem cell therapies have been successfully performed and approved in the form of bone marrow transplants and more recently, in skin and corneal grafting. However, the field of regenerative cell therapy has somewhat come to a halt due to safety, ethical and legal concerns associated with medical and scientific practices. In Australia, stem cell therapies, besides those mentioned above, are permitted provided that they are autologous in nature and that the procedure is performed by or under the supervision of a registered medical practitioner in a single treatment. However, the medical practitioner requires no formal stem cell training. We have identified this deficiency in optimal patient care and propose that education in the safe, legal and ethical delivery of stem cell treatments be part of a mandatory training course for medical/dental practitioners and the scientific team prior to the clinical use of stem cell therapies in Australia, and arguably, on a global scale. This involves the scientific and medical team having a sound understanding of the biology of stem cells, their appropriate applications and basic validation and laboratory techniques in order to provide effective and safe treatment for improved patient outcomes. As such, this article aims to propose a frame-work of scientific guidelines for dental and medical practitioners to undertake stem cell therapies.

Keywords: Adipose-derived stem cells; Mesenchymal stem cells; Regenerative medicine; Stem cells

Introduction

Bone tissue has the ability to regenerate without leaving scars. However, major injury repair of bone tissue caused by trauma, cancer or other bone disease remains a challenge for orthopedic surgeons [1]. Autologous bone transplantation still has deficiencies such as limited autologous tissue available to repair bone damage, donor morbidity, possible wound infections, and longer surgery [2]. An allogenic transplant given to the patient can be a good alternative, but this technique can increase the risk of rejection and disease spread [3]. Therefore, it is necessary to develop a new strategy to improve the technique of bone regeneration.

New developments in the field of cell therapy have provided a new approach in the improvement of bone tissue. Mesenchymal stem cells (MSCs) are multipotent stem cells that can renew themselves and differentiate into several lines, such as adipogenic, condenset and osteogenic precursors [4]. The ability to self-renew and differentiate into osteoblast cells makes the MSCs as a good cell source for bone tissue engineering. Among the various types of MSCs sources, mesenchymal stem cells of adipose tissue origin are multipotent cells that are readily available in abundant amounts and can be isolated by relatively harmless procedures [5]. Establishment of osteoblast cells from MSCs from adipose tissue has tremendous value in developing and evaluating methods to bone regeneration process [1-15].

The application of cell biology and tissue culture generally requires cell proliferation in vitro to obtain sufficient cell numbers, with most studies using stem cells in passages 1 through 5. However, further research on the MSC capability of adipose tissue origin in maintaining stem cell characteristics and the potential for differentiation in longterm subcultures. Through the above description, this study aims to evaluate the effect of the initial passage (passage ≤ 5, with passages 2 and 5), middle (passages> 5-10, with passage 10) and old (passage ≥15, 15) to the differentiation potential of MSC from adipose tissue to osteoblast cells. Osteogenic differentiation in vitro can be done by implanting MSC into induction media. The osteogenesis induction media component generally consists of dexamethasone (DEX), L-ascorbic acid 2 phosphates (ASC) and β-glycerophosphate (β-GP) added to cell culture medium for osteogenic differentiation. Each component has been shown to support MSC osteogenic differentiation in vitro [6].

Material and Methods

Isolation of MSC of adipose tissue

Adipose tissue is obtained from a healthy human donor with the approval of a medical action at Clinic with the methodology used already approved by the applicable code of ethics. Adipose fat tissue was isolated enzymatically by collagenase. Incubated at 5% CO2, 37°C; if the cell reaches 80% confluency, the cell is ready to use for this experiments (Figure 1).

stem-cell-research-therapy-osteoblasts-supplements

Figure 1: The scheme of forming the MSC stage into osteoblasts and the role of supplements in the induction of osteogenesis.

MSC culture of adipose tissue

After the isolation process, the MSC of adipose tissue was grown in a growing medium composed of Alpha-Minimum Essential Medium (α-MEM) with supplementation of penicillin-streptomycin and serum incubated at 37°C and 5% CO2 incubator. The growth medium is replaced every 3 days and was calculated (0.05% trypsin-EDTA; Sigma) when the cell has reached a confluence. Cells are subcultured every 3-5 days and propagated to reach passage 3.

Optimization of osteogenic media composition

For optimization of osteogenic media composition, MSC was grown in containers containing growing media supplemented with the following osteogenic components.

For the comparison of each osteogenic medium, the cells were grown in growing media, i.e. α-MEM + 2.5% serum or α-MEM + 5% serum and incubated for several hours before initiating differentiation using osteogenic differentiation media [16-30].

Osteogenic differentiation

Osteogenic differentiation was performed using cell passage variation and incubation time (Tables 1 and 2). Passages used were divided into three groups, namely early passage (passage 2 and 5), middle passage (passage 10), and late passage (passage 15). Each passage is incubated within 1, 4, 7, 10 and 14 days.

Media α-MEM + 5% serum α-MEM + 2,5% serum
ODM1 100 nM Dex,
50 µg/mL Asc,
10 mM β-GP
100 nM Dex,
50 µg/mL Asc,
10 mM β-GP
ODM2 10 nM Dex,
200 µM Asc,
10 mM β-GP
10 nM Dex,
200 µM Asc,
10 mM β-GP
ODM3 5 nM Dex,
250 µM Asc,
10 mM β-GP
5 nM Dex,
250 µM Asc,
10 mM β-GP
ODM:  Osteogenic Differentiation Media; Serum; Dex, dexamethasone; AsA2-F, L-ascorbic acid 2-phosphate; β-GP, beta-glycerophosphate

Table 1: The composition of the media used in the study.

Passage Incubation Time (Day)
Passage 2 1 4 7 10 14
Passage 5
Passage 10
Passage 15

Table 2: Optimization of cell passages and incubation time.

In each incubation time at each passage, there are two dishes consisting of control and treatment. The control media and osteogenic differentiation media used were selected based on the optimum osteogenic composition of the media.

Alizarin red staining

Cells grown in growth medium and osteogenic media for 1, 4, 7, 10 and 14 days were fixed using formalin 10% for 24 hours. After fixation, the cell was then stained using Alizarin red dye and incubated for approximately three hours. Visualization of Alizarin red coloring results was performed using an inverted microscope.

Result and Discussion

Optimization of osteogenic media composition

Preliminary research was conducted to determine the most efficient osteogenic composition of media in inducing osteogenesis in MSCs of adipose tissue. MSC from passage 3 is grown in different osteogenic media and incubated for five days. After five days, each culture container was characterized using Alizarin red staining (Figure 2).

stem-cell-research-therapy-osteogenic-media-optimization

Figure 2: MSCs staining results of adipose tissue for osteogenic media optimization. MSCs were cultured in six different osteogenic media for five days and stained by using 1% Alizarin red dye.

In Figure 2, it was shown that MSC differentiation results using ODM 1 showed significant differences compared with ODM 2 and ODM 3. In addition, the use of serum with lower concentrations resulted in relatively fewer cell counts than MSCs cultured in concentrations of 5% serum. Generally, osteogenic differentiation of MSCs in vitro culture is performed using ODM 1. However, this osteogenic medium was originally used for MSCs differentiation from bone marrow [31-51].

Although MSC from bone marrow and adipose tissue have many similar characteristics, their response to induction factors is not necessarily identical. Therefore, ODM 1 used in this study is still not able to induce osteogenic differentiation well because its component concentration has not been optimized for MSC differentiation of adipose tissue origin. To determine the optimal osteogenic media, ODM 2 and ODM 3 used in this study were made with lower dexamethasone compositions and higher ascorbic acid compared with ODM 1. Based on this research, ODM 2 and ODM 3 may induce osteogenic differentiation more good compared to ODM 1.

The influence of osteogenic media on cell count depends on serum conditions. In the α-MEM + 2.5% serum condition, the number of cells tends to be less than using α-MEM + 5% serum. Appropriate serum concentrations are needed to increase cell growth, so the use of serum 2.5% serum is still not able to support MSC growth optimally.

The characterization results show that ODM 2 using growing media α-MEM + 5% serum can produce the most optimal osteoblast differentiation compared to other media. This suggests that the results of this study are in accordance with research conducted by de Girolamo. suggesting that higher use of ascorbic acid concentrations and lower dexamethasone may induce osteogenesis in MSCs of adipose tissue well. High concentrations of ascorbic acid are reported to stimulate the proliferation of MSC from bone marrow and cells such as osteoblasts without loss of potential differentiation. Several studies have emphasized the importance of ascorbic acid in osteogenic differentiation of MSC from bone marrow and cells such as osteoblasts. On the other hand, dexamethasone in high concentrations has shown inhibition of osteogenic differentiation, although dexamethasone is required in low concentrations for effective MSC osteogenic induction . Through the above description, the media differentiation used in the next step to induce osteogenic differentiation is ODM 2.

Effect of passage on osteogenic potential of MSC of adipose tissue

The MSCs from the isolated adipose tissue are then proliferated to certain passages, in passages 2, 10 and 15. The lifespan of the human MSC can be categorized into the initial passage (≤5), the middle passage (> 5-10) and the old passage (≤ 15), based on the proliferative ability and percentage of senescence-associated beta-galactosidase (SA-β-gal, biomarker for senescence cells), as has been previously proposed. MSC was administered using dexamethasone, 2-phosphate ascorbic acid and β-glycerophosphate for 14 days to initiate osteogenic differentiation. The osteogenic potential is measured qualitatively by using Alizarin red, which is a colorant that gives color to calcium deposition.

The incubation time is an important factor in determining the length of time required to induce MSC differentiation from adipose tissue to osteoblasts. In general, osteogenic differentiation is divided into three stages: cell proliferation, extracellular matrix maturation and matrix mineralization. Cell proliferation can occur on days 1-4, followed by maturation of extracellular matrix on days 5-14 and end with mineralization of the matrix on days 14-28. Mineralization can be detected since the 14th day of induction and increased to 21 days. Generally, mineralization begins after osteoblast proliferation and formation of extracellular matrix (mostly collagen). Previous studies have suggested that mineralization may increase in speed as cell proliferation slows due to high cell density.

In this study, since induction of osteogenesis on day 1, most of the positive Alizarin red staining results can already be seen. After being cultured for one day in osteogenic differentiation media, the cells of the three passages have begun to change from the initial morphology, i.e. fibroblasts to slightly round. After incubation for 7 days, a number of mineralized nodules can be observed and an increase in cell volume in passages 10 and 15. A number of studies have shown that cell volume changes are a component of many cellular functions, including epithelial transport, metabolism, hormone release, migration, proliferation and cell growth and cell death (Figure 3).

stem-cell-research-therapy-cultures-passage

Figure 3: MSC cultures in passage 10 that have been incubated in ODM2 for 14 days. Images taken using 400x magnification.

In general, cell volume regulation does have an important role in cell proliferation and growth, but the role of cellular volume regulation in osteoblast lineages remains unclear. Furthermore, at the 14th incubation day, the mineralized nodule density becomes more stable at passage 10, indicating that the cell has reached a relatively stable differentiated condition (Figure 4). During the incubation period of 14 days, the cells in passage 2 showed no significant change when compared with other passages, while the cells in passage 15 showed an increase that could still be seen daily. On the 14th day, cell cultures in passage 10 have reached a confluence, so when compared with cell cultures in passages 5 and 15, passage 10 images are seen taken with smaller magnification. Figure 3 shows the osteogenic differentiation picture of MSC passage 10 with 400x magnification.

stem-cell-research-therapy-osteogenic-potential

Figure 4: Comparison of osteogenic potential of MSC of origin of adipose tissue on the initial, middle and old passages. All photos with 200x magnification.

Based on the results of this study, the MSC of the adipose tissue in passage 2 had the fewest number of cells and the differentiated ability to be the lowest osteoblast. As explained by Kuznetsov et al. and Satomura et al. [26,40] the colonies obtained when planting MSCs in the initial passage are heterogeneous colonies in size, morphology and potential to differentiate into osteoblasts. In this study, cultures in the early passages were also heterogeneous in the potential to differentiate into osteoblasts in cultures, so the osteogenic potential of MSCs were not equal. In addition, when MSCs were first cultured in vitro, the MSCs still retains the characteristics of its stem cells and takes time to adapt to new environmental conditions, thus making it difficult to differentiate. This can then be the cause of osteogenic potential of MSC in passage 2 lower than other passages. On the other hand, in passage 10, the MSCs are able to differentiate into osteoblasts with relatively much greater number of cells than passages 2 and 15 because the MSCs has been adaptable and relatively stable in culture. The potential for osteogenic differentiation in passage 15 was sustained although the number of osteoblast cells formed is still less than in passage 10. This is probably due to MSCs has undergone senescence, resulting in a decrease in cell proliferation capacity and may also lead to decreased osteogenic potential of MSCs, however it need further study .

Several studies have shown that the osteogenic activity of MSCs has decreased gradually as the passage increases. On the other hand, there are other studies suggesting that the osteogenic potential of MSC in the old passage can be maintained or even increased. Differences in the results of studies related to increased or decreased osteogenic ability of MSC with senescence are likely to occur due to differences in culture conditions and the lack of optimal in vitro testing to characterize osteogenesis completely. Turinetto et al. [43] found that increased cell death could result in higher levels of Alizarin red staining, resulting in misperceptions about increased osteogenic differentiation.

In the in vitro approach, the number of subcultures that the MSC can do without altering its characteristics significantly needs more attention. Kim et al. [25] suggests that in vitro (number of passages in culture) has a more significant effect on MSC differentiation than in vivo (donor physical). In this study, the MSC from adipose tissue managed to maintain its differentiation potential to passage 15 and increased the differentiation potential from passage 2 to passage 10. The decrease in cell number in passage 15 could be caused by cell senescence. However, osteogenic differentiation can still occur in both the initial, middle and old passages. The results show that the osteogenic potential of MSC from adipose tissue does not decrease with age aging in vitro. This is an exciting discovery because the ability to repair damaged tissue will in reality decline with age.

Summary

Based on the results obtained, it can be concluded that the MSC was able to maintain its osteogenic potential until passage 15. The result of osteogenic differentiation by using α-MEM culture medium supplemented with 5% serum and dexamethasone, ascorbic acid and beta-glycerophosphate indicate that passage 10 (middle passage) has the best osteogenic potential compared to other passages, while the lowest osteogenic potential is seen in MSC passage 2.

References

Citation: Shparberg R, Braunsteiner N, Vickers ER (2018) Laboratory Training Guidelines for Clinicians Undertaking Stem Cell Therapy. J Stem Cell Res Ther 8: 427. Doi: 10.4172/2157-7633.1000426

Copyright: © 2018 Shparberg R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
  • 4th International Conference on Bioscience July 2-3, 2018 Vienna, Austria

    July 2-3, 2018 Vienna, Austria

  • 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand

    April 16-18, 2018 Amsterdam, Netherlands

  • 9th International Conference on Tissue Science and Regenerative Medicine July 13-14, 2018 Sydney, Australia

    April 23-24, 2018 Las Vegas, USA

  • 10th Annual Conference on Stem Cell and Regenerative Medicine August 13-14, 2018 London, UK

    August 13-14, 2018 London, UK

  • World Congress on Stem Cell Biology and Biobanking September 3-4, 2018 Tokyo, Japan

    September 3-4, 2018 Tokyo, Japan

  • 2nd Annual summit on Cell Metabolism and Cytopathology September 19 - 20, 2018 Philadelphia, Pennsylvania, USA

    September 19 - 20, 2018 Philadelphia, USA

  • 2nd Annual summit on Cell Signaling and Cancer Therapy September 19 - 20, 2018 Philadelphia, Pennsylvania, USA

    September 19 - 20, 2018 Philadelphia, USA

  • 6th Annual Congress on Biology and Medicine of Molecules September 20-21,2018 Kuala Lumpur, Malaysia

    September 20-21,2018 Kualalumpur, Malaysia

  • 5th International Conference on Human Genetics and Genetic Disorders September 21-22,2018 Philadelphia, Pennsylvania, USA

    September 21-22,2018 Philadelphia, USA

  • 11th International Conference on Genomics and Pharmacogenomics September 21-22, 2018 Philadelphia, Pennsylvania, USA

    September 21-22, 2018 Philadelphia, USA

  • 5th World Congress on HUMAN GENETICS SEPTEMBER 24-25, 2018 BERLIN, GERMANY

    SEPTEMBER 24-25, 2018 Berlin, Germany

  • 21st Euro Biotechnology Congress October 11-12, 2018 Moscow, Russia

    October 11-12, 2018 Moscow, Russia

  • 11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy

    October 18-20, 2018 Rome, Italy

  • 24th Biotechnology Congress: Research & Innovations October 24-25, 2018 Boston, USA

    October 24-25, 2018 Boston, USA

  • International Conference on Human Genome Meeting October 25-26, 2018 Istanbul, Turkey

    October 25-26, 2018 Istanbul, Turkey

  • International Congress & Expo on Genomics and Bioinformatics November 2-3, 2018 Columbus, Ohio, USA

    November 2-3, 2018 Columbus, USA

  • 12th International Conference & Exhibition on Tissue Preservation and Biobanking November 9-10, 2018 Atlanta, Georgia, USA

    November 9-10, 2018 Atlanta, USA

  • 2nd Annual Summit on Cell Therapy and Stem Cell Research November 9-10, 2018 Atlanta, Georgia, USA

    November 9-10, 2018 Atlanta, USA

Article Usage
  • Total views: 100
  • [From(publication date): 0-2018 - Jun 22, 2018]
  • Breakdown by view type
  • HTML page views: 81
  • PDF downloads: 19

Post your comment

captcha   Reload  Can't read the image? click here to refresh
Leave Your Message 24x7